Hematopoietic stem cell donor registry strategies for assigning search determinants and matching relationships

Hurley, C. K.; Setterholm, M.; Lau, M.; Pollack, M. S.; Noreen, H.; Howard, A.; Fernandez-Vina, M.; Kukuruga, D.; Müller, C. R.; Venance, M.; Wade, J. A.; Oudshoorn, M.; Raffoux, C.; Enczmann, J.; Wernet, P.; Maiers, M.
February 2004
Bone Marrow Transplantation;Feb2004, Vol. 33 Issue 4, p443
Academic Journal
Summary:Registries and cord blood banks around the world collect and store the HLA types of volunteers in order to identify matched unrelated donors for patients requiring hematopoietic stem cell transplantation. This task is complicated by the many formats in which HLA types are provided by the testing laboratories (types obtained by serology vs by DNA-based methods; high vs intermediate vs low resolution) and by the need to identify which of these diverse types are most likely to match the HLA assignments of a searching patient as closely as possible. Conversion of the assignments to ‘search determinants’ may be included within the algorithm used to select and prioritize a list of potentially suitable donors, either as an aid to matching or as a tool to optimize the performance of comparisons within large data files. The strategies used by registries to create search determinants are described. A set of search determinants, utilized by the National Marrow Donor Program, is provided as an example and is intended to initiate further discussion aimed at understanding the process used by each registry with the possibility of developing a standard process among registries worldwide.Bone Marrow Transplantation (2004) 33, 443-450. doi:10.1038/sj.bmt.1704365 Published online 15 December 2003


Related Articles

  • Five things to know about . . . Donation and transplantation of allogeneic hematopoietic stem cells. Kopolovic, Ilana; Turner, Robert // CMAJ: Canadian Medical Association Journal;11/22/2011, Vol. 183 Issue 17, p2014 

    The article presents five things to know regarding allogeneic hematopoietic stem cells donation and transplantation in Canada. It states that only 30% of Canadian patients with indications for an allogeneic stem cell transplant have a matched related donor, while 70% seek an unrelated donor on...

  • Regionally limited or rare infections: prevention after hematopoietic cell transplantation. Gea-Banacloche, J; Masur, H; da Cunha, C Arns; Chiller, T; Kirchhoff, L V; Shaw, P; Tomblyn, M; Cordonnier, C // Bone Marrow Transplantation;Apr2010, Vol. 45 Issue 4, p806 

    A correction to the article "Guidelines for preventing infectious complications among hematopoietic cell transplant recipients: a global perspective" that was published in 2009 issue is presented.

  • Incidence, outcome, and risk factors of late-onset noninfectious pulmonary complications after unrelated donor stem cell transplantation. Fanin, R; Patriarca, F.; Skert, C.; Sperotto, A.; Damiani, D.; Cerno, M.; Geromin, A.; Zaja, F.; Stocchi, R.; Prosdocimo, S.; Fili, C. // Bone Marrow Transplantation;Apr2004, Vol. 33 Issue 7, p751 

    Summary:We evaluated the incidence, the risk factors, and the outcome of late-onset noninfectious pulmonary complications (LONIPCs) among 50 patients who underwent allogeneic stem cell transplantation from unrelated donors. Of the 39 patients surviving at least 3 months, 10 (26%) fulfilled the...

  • Application of machine learning algorithms for clinical predictive modeling: a data-mining approach in SCT. Shouval, R; Bondi, O; Mishan, H; Shimoni, A; Unger, R; Nagler, A // Bone Marrow Transplantation;Mar2014, Vol. 49 Issue 3, p332 

    Data collected from hematopoietic SCT (HSCT) centers are becoming more abundant and complex owing to the formation of organized registries and incorporation of biological data. Typically, conventional statistical methods are used for the development of outcome prediction models and risk scores....

  • Allogeneic hematopoietic stem cell transplantation in Tunisia. Othman, T. Ben; Torjemane, L.; Abdelkefi, A.; Lakhal, A.; Ladeb, S.; Hamed, L. Ben; Slama, H.; Abdeladhim, A. Ben // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS139 

    In 1998, the Tunisian team of the ‘Centre National de Greffe de Moelle Osseuse’ initiated allogeneic hematopoietic SCT (AHSCT) in Tunisia. As of June 2007, information was collected about 299 patients with a first AHSCT and 12 additional retransplants. The median age was 19 years...

  • Hematopoietic stem cell transplantation in Oman. Dennison, D.; Al Kindi, S.; Pathare, A.; Daar, S.; Nusrat, N.; Rehman, J. Ur; Zia, F.; Khan, H.; Khan, M. Irfan; Alghazaly, A.; Al-Zadjali, S.; Tauro, M.; Al Lawatia, A. T.; Ganguly, S. S. // Bone Marrow Transplantation;Aug2008 Supplement, Vol. 42, pS109 

    Hematopoietic SCT (HSCT) is an integral part of the management of patients with hematologic disorders. The Sultanate of Oman, with a population of 2.3 million, has an HSCT program based in the Sultan Qaboos University (SQU) hospital. Initiated in 1995, this two-bed unit continues to be the only...

  • Role of HLA in hematopoietic SCT. Nowak, J. // Bone Marrow Transplantation;Oct2008 Supplement, Vol. 42, pS71 

    HLA disparity between hematopoietic stem cell (HSC) donor and recipient triggers T-cell and NK-cell allorecognition, and induces the GVHD, GVL effect and/or may cause an engraftment failure. This review will cover the scope of human genomic variation, the methods of HLA typing and interpretation...

  • Chances of finding a matched parent-child in hematopoietic stem cell transplantation in Saudi Arabia. Hajeer, Ali H.; Algattan, Manal; Anizi, Aisha; Alaskar, Ahmed S.; Jarrar, Mohammad S. // American Journal of Blood Research;2012, Vol. 2 Issue 3, p201 

    The article discusses the higher chances of Saudi Arabian patients awaiting hematopoietic stem cell transplantation (HSCT) to find a matched sibling donor. Researchers found that adult patients had 68% of finding related donors, mainly due to family size. Due to the relatively high chance of...

  • Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors. Sedlacek, P.; Mejstrikova, E.; Formankova, R.; Keslova, P.; Dobrovolna, M.; Vrana, M.; Stary, J. // Bone Marrow Transplantation;Oct2008 Supplement, Vol. 42, pS10 

    Allogeneic HSCT is a curative treatment for high-risk leukemia. In Europe, approximately 15% of children have an HLA-matched sibling, but in 65–70% HLA allele-matched (9–10/10) unrelated donors (UD) can be identified. Transplantation using an HLA partially mismatched donor,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics